


Amendments to the Claims

This listing of claims will replace all prior versions, and listing, of claims in the application.

Listing of Claims


1. (currently amended): A compound of formula (I):



(I)

wherein

R^1 is n-propyl, 1-methylethyl, 2-methylpropyl, or 3,3-dimethylpropyl; ~~(optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from S-(C₁-C₃-alkyl), O-(C₁-C₃-alkyl) (optionally substituted with 1, 2 or 3 F atoms), O-(C₃-C₆-cycloalkyl), SO₂-(C₁-C₃-alkyl), CN, COO-(C₁-C₂-alkyl) and OH); C₂-C₆-alkenyl; (CH₂)_q-Ar₂; or a group of formula (i) or (ii)~~



(i) (ii)

R^2 , R^3 and R^4 are each independently selected from hydrogen or C₁-C₂ alkyl;
 ~~R^5 , R^6 , R^7 and R^8 are each independently selected from hydrogen or C₁-C₂ alkyl;~~
~~X is a bond, CH₂, CH=CH, O, S, or SO₂;~~
~~Y is a bond, CH₂ or O;~~
~~Z is hydrogen, OH or O-(C₁-C₃-alkyl);~~
~~p is 0, 1 or 2;~~
~~q is 0, 1 or 2;~~
~~r is 0 or 1;~~
~~s is 0, 1, 2 or 3;~~
~~t is 0, 1, 2, 3 or 4; and~~

Ar_1 is selected from: a phenyl group which is optionally substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1 - C_4 alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents; pyridinyl; or pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1 - C_4 alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents; and

Ar_2 is selected from

- (i) ~~a phenyl group or a 5- or 6-membered monocyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1 - C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), O (C_1 - C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and S (C_1 - C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1 - C_4 alkyl may be a substituent for the H of any NH moiety present within a 5- or 6-membered monocyclic heteroaromatic group; or~~
- (ii) ~~a naphthyl group or an 8-, 9- or 10-membered bicyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1 - C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), O (C_1 - C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and S (C_1 - C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1 - C_4 alkyl may be a substituent for the H of any NH moiety present within an 8-, 9- or 10-membered bicyclic heteroaromatic group;~~

or a pharmaceutically acceptable salt thereof

- (a) ~~the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms;~~
- (b) ~~when X is $CH=CH$, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms;~~
- (c) ~~when Z is OH or O (C_1 - C_3 alkyl), then X is CH_2 ;~~

~~(d) when Y is O then p cannot be 0.~~

2. (canceled)

3. (canceled)

4. (currently amended): The compound of claim 1, wherein R^2 , R^3 , and R^4 [[,]] R^5 , R^6 , R^7 , and R^8 are each hydrogen.

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled).

18. (canceled).

19. (previously presented): The compound of claim 1, wherein $-Ar_1$ is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1-C_4 alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents.

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (previously presented): A pharmaceutical composition, comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

Claims 25 - 28. (canceled)

29. (previously presented): A method for treating attention-deficit hyperactivity disorder (ADHD), comprising administering to a patient in need thereof an effective amount of a compound of claim 1 which selectively inhibits the reuptake of norepinephrine over serotonin and dopamine, or a pharmaceutically acceptable salt thereof.

Claims 30-36. (canceled).